BALTIMORE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Urology Care Foundation (UCF), the official foundation of the American Urological Association (AUA), and the Prostate Cancer Foundation (PCF) today ...

Genomic profiling revealed druggable targets in 39% of advanced prostate cancer cases, guiding personalised treatments.

A systematic review found that genomic classifier tests can influence risk assessments and treatment decisions among patients with localized prostate cancer but studies evaluating these tests vary ...

New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...

Clinical Implementation of Expanded Solid Tumor Fusion Detection With Whole-Transcriptome Sequencing at an Academic Cancer Center One hundred twenty-two participants completed the survey. The majority ...

The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...

Scientist examining genetic testing results on a screen High-grade tumors do not directly evolve from lower-grade ones, but both likely emerge from a common, pre-malignant mutagenic field. A recent ...

Prostate Cancer is the second leading cause of death in American men after lung cancer. In 2018, 165,000 men will be diagnosed with prostate cancer. The question all men with prostate cancer need ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

Please provide your email address to receive an email when new articles are posted on . Black men with prostate cancer had significantly greater odds of having alterations in immunotherapy targets ...

Findings could improve screening and treatment for patients of African ancestry HEALTH REPORT | THE INDEPENDENT & AGENCIES | ...